Radiomics diagnosed histopathological growth pattern in prediction of response and 1-year progression free survival for colorectal liver metastases patients treated with bevacizumab containing chemotherapy

doi:10.1016/j.ejrad.2021.109863

	Radiomics diagnosed histopathological growth pattern in prediction of response and 1-year progression free survival for colorectal liver metastases patients treated with bevacizumab containing chemotherapy
	Wei, Shengcai 1; Han, Yuqi 2; Zeng, Hanjiang 3; Ye, Shuai 4; Cheng, Jin 1; Chai, Fan 1; Wei, Jingwei5,6 ; Zhang, Jianwei 7; Hong, Nan 1; Bao, Yudi 8; Zhou, Jing 8; Ye, Yingjiang 8; Meng, Xiaochun 4; Zhou, Yuwen 9; Deng, Yanhong 7; Qiu, Meng 9; Tian, Jie 5,6,10,11; Wang, Yi 1
发表期刊	EUROPEAN JOURNAL OF RADIOLOGY
ISSN	0720-048X
	2021-09-01
卷号	142 页码:8
通讯作者	Tian, Jie(tian@ieee.org) ; Wang, Yi(wangyi@pkpuh.edu.cn)
摘要	Objective: To investigate the capability of a radiomics model, which was designed to identify histopathologic growth pattern (HGP) of colorectal liver metastases (CRLMs) based on contrast-enhanced multidetector computed tomography (ceMDCT), to predict early response and 1-year progression free survival (PFS) in patients treated with bevacizumab-containing chemotherapy. Methods: Patients with unresectable CRLMs who were treated with bevacizumab-containing chemotherapy were included in this multicenter retrospective study. For each target lesion, the radiomics-diagnosed HGP (RAD_HGP) of desmoplastic (D) pattern or replacement (R) pattern was determined. Logistic regression and receiver operating characteristic (ROC) curves were used to assess lesion- and patient-based responses according to morphologic response criteria. One-year PFS was calculated using Kaplan-Meier curves. Hazard ratios for 1-year PFS were obtained through Cox proportional hazard regression analysis. Results: Among 119 study patients, 206 D pattern and 140 R pattern lesions were identified. In patients with multiple lesions, 52 had D pattern, 31 had R pattern, and 36 had mixed (D + R) pattern. The area under the curve value for RAD_HGP in predicting early response was 0.707 for lesion-based analysis and 0.720 for patient-based analysis. Patients with D pattern had a significantly longer PFS than patients with R pattern or mixed pattern (P < 0.001). RAD_HGP was the only independent predictor of 1-year PFS. Conclusions: HGP diagnosed using a radiomics model could be used as an effective predictor of PFS for patients with CRLMs treated with bevacizumab-containing chemotherapy.
关键词	Histopathologic growth pattern Colorectal liver metastases Unresectable Radiomics Bevacizumab
DOI	10.1016/j.ejrad.2021.109863
关键词[WOS]	ANTI-ANGIOGENIC THERAPY ; COMPUTED-TOMOGRAPHY ; CANCER ; CRITERIA
收录类别	SCI
语种	英语
资助项目	Nature Science Foundation of Beijing[7202217] ; Peking University People's Hospital Research and Development Funds[RS2019-05] ; Peking University People's Hospital Research and Development Funds[RDX2019-01] ; Ministry of Science and Technology of China[2016YFC0103803] ; Ministry of Science and Technology of China[2016YFA0201401] ; Ministry of Science and Technology of China[2016YFC0103702] ; Ministry of Science and Technology of China[2017YFC1308700] ; Ministry of Science and Technology of China[2017YFC1309100] ; Ministry of Science and Technology of China[2017YFA0205200] ; National Natural Science Foundation of China[82001917] ; National Natural Science Foundation of China[81930093] ; National Natural Science Foundation of China[81527805] ; National Natural Science Foundation of China[81771924] ; Chinese Academy of Sciences[QYZDJ-SSW-JSC005]
项目资助者	Nature Science Foundation of Beijing ; Peking University People's Hospital Research and Development Funds ; Ministry of Science and Technology of China ; National Natural Science Foundation of China ; Chinese Academy of Sciences
WOS研究方向	Radiology, Nuclear Medicine & Medical Imaging
WOS类目	Radiology, Nuclear Medicine & Medical Imaging
WOS记录号	WOS:000687950400005
出版者	ELSEVIER IRELAND LTD
七大方向——子方向分类	医学影像处理与分析
引用统计	被引频次：14[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.ia.ac.cn/handle/173211/45915
专题	中国科学院分子影像重点实验室
通讯作者	Tian, Jie; Wang, Yi
作者单位	1.Peking Univ Peoples Hosp, Dept Radiol, 11 Xizhimen South St, Beijing 100044, Peoples R China 2.Xidian Univ, Sch Life Sci & Technol, 266 Xinglong Sect Xifeng Rd, Xian 710126, Shanxi, Peoples R China 3.Sichuan Univ, Dept Radiol, West China Hosp, 37 Guoxue Xiang St, Chengdu 610041, Sichuan, Peoples R China 4.Sun Yat Sen Univ, Dept Radiol, Affiliated Hosp 6, Guangzhou 510655, Peoples R China 5.Chinese Acad Sci, Inst Automat, Key Lab Mol Imaging, 95 Zhongguancun East Rd, Beijing 100190, Peoples R China 6.Beijing Key Lab Mol Imaging, Beijing 100190, Peoples R China 7.Sun Yat Sen Univ, Dept Med Oncol, Affiliated Hosp 6, Guangzhou 510655, Peoples R China 8.Peking Univ Peoples Hosp, Dept Gastrointestinal Surg, 11 Xizhimen South St, Beijing 100044, Peoples R China 9.West China Hosp Sichuan Univ, Canc Ctr, Dept Med Oncol, 37 Guoxue Xiang St, Chengdu 610041, Sichuan, Peoples R China 10.Beihang Univ, Beijing Adv Innovat Ctr Big Data Based Precis Med, Sch Med, Beijing 100191, Peoples R China 11.Xidian Univ, Engn Res Ctr Mol & Neuro Imaging Minist Educ, Sch Life Sci & Technol, Xian 710126, Peoples R China
通讯作者单位	中国科学院自动化研究所; 中国科学院分子影像重点实验室
推荐引用方式 GB/T 7714	Wei, Shengcai,Han, Yuqi,Zeng, Hanjiang,et al. Radiomics diagnosed histopathological growth pattern in prediction of response and 1-year progression free survival for colorectal liver metastases patients treated with bevacizumab containing chemotherapy[J]. EUROPEAN JOURNAL OF RADIOLOGY,2021,142:8.
APA	Wei, Shengcai.,Han, Yuqi.,Zeng, Hanjiang.,Ye, Shuai.,Cheng, Jin.,...&Wang, Yi.(2021).Radiomics diagnosed histopathological growth pattern in prediction of response and 1-year progression free survival for colorectal liver metastases patients treated with bevacizumab containing chemotherapy.EUROPEAN JOURNAL OF RADIOLOGY,142,8.
MLA	Wei, Shengcai,et al."Radiomics diagnosed histopathological growth pattern in prediction of response and 1-year progression free survival for colorectal liver metastases patients treated with bevacizumab containing chemotherapy".EUROPEAN JOURNAL OF RADIOLOGY 142(2021):8.